<DOC>
	<DOCNO>NCT00301522</DOCNO>
	<brief_summary>The primary objective study evaluate safety effectiveness TAXUS Express2 Paclitaxel-Eluting Coronary Stent System long lesion length , small large vessel diameter multiple overlap stent treatment de novo coronary artery lesion</brief_summary>
	<brief_title>Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents Treat De Novo Coronary Lesions</brief_title>
	<detailed_description>The primary endpoint incidence rate TVR 9 month post index procedure . In protocol , TVR must ischemia driven , base presence symptom , positive functional test Quantitative Coronary Angiography ( QCA ) severity restenosis . Secondary endpoint include follow : - Incidence rate composite MACE individual component MACE assess discharge , 1 , 4 9 month post index procedure annually 5 year ( i.e. , 1 , 2 , 3 , 4 5 year post index procedure ) . - Stent thrombosis rate . - TVF . - Clinical procedural success technical success . - Binary restenosis rate . - Additional angiographic endpoint measure patient 9 month angiographic follow-up include : - Absolute lesion length - Reference Vessel Diameter ( RVD ) - Minimum Lumen Diameter ( MLD ) - Percent diameter stenosis ( % DS ) - Acute gain - Late loss - Loss index - Patterns recurrent restenosis , include edge effect - Coronary aneurysm - IVUS Substudy - Identification potential safety issue , i.e. , incomplete stent apposition . - change neointimal volume post procedure follow-up - change MLD within stent - minimum lumen area ( MLA ) within stent - lumen , plaque vessel measurement stent edge ( outside stent )</detailed_description>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient ≥ 18 year old . Eligible percutaneous coronary intervention . Documented stable angina pectoris . LVEF great 25 % . Acceptable candidate coronary artery bypass grafting . Target lesion segment locate within single native coronary vessel . Target lesion de novo . RVD great 2.25 mm less 4.0 mm .and patient and/or lesion fulfil protocol define subgroup . Cumulative target lesion length great 10 mm less 46mm assessed predilatation standard balloon cut balloon angioplasty , include adjacent area dissection cover . Target lesion diameter stenosis le 50 % predilatation . Vessel lesion morphology lesion treat study stent ( ) ; plan use commercial stent . Known hypersensitivity paclitaxel . Any previous plan treatment nonstudy antirestenotic drugcoated drugeluting coronary stent . Planned use study stent nonstudy stent treatment target vessel . Previous plan treatment intravascular brachytherapy target vessel . Recent MI . CKMB great 2x local laboratory 's upper limit normal . Cerebrovascular accident within 6 month randomization . Planned CABG ≤ 9 month post index procedure . Acute chronic renal dysfunction . Leukopenia . Thrombocytopenia thrombocytosis . Active peptic ulcer active gastrointestinal bleeding , previously active within 6 month . Known allergy stainless steel . Any prior true anaphylactic reaction contrast agent . Contraindication ASA clopidogrel ticlopidine . Patient warfarin anticipate treatment warfarin would require period within 6 month post index procedure . Patient treat chemotherapeutic agent within 12 month index procedure . Anticipated treatment paclitaxel , oral rapamycin colchicine period 9 month post index procedure . Male female know intention procreate within 3 month post index procedure . Comorbid condition ( ) could limit patient 's ability participate study , limit compliance followup requirement impact scientific integrity study . Planned surgical procedure require withdrawal antiplatelet therapy within 6 month post index procedure . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study . Unprotected leave main coronary artery disease . Target lesion ostial location . Target lesion and/or target vessel proximal target lesion moderately severely calcify . Target lesion locate within distal &gt; 60° bend vessel . Side branch target lesion include ostial narrowing ≥ 50 % DS ≥ 2.0 mm diameter . Target lesion totally occlude . Angiographic presence probable definite thrombus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Coronary</keyword>
	<keyword>Artery</keyword>
	<keyword>Stenosis</keyword>
	<keyword>Drug-eluting</keyword>
	<keyword>stent</keyword>
	<keyword>restenosis</keyword>
	<keyword>revascularization</keyword>
</DOC>